Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
ConditionRectal Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking Union Medical College Hospital
About this trial
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
pathologically confirmed rectal adenocarcinoma
located within 12cm below the anal verge
Disqualifiers
diagnosed with distant metastasis
multiple primary colorectal cancers
history of previous malignant tumors
Pregnant or lactating women
Trial population
mid-low rectal cancer patients
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Registry study, no specific intervention
Other interventionRegistry study, no specific intervention
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
3-year OS
3-year overall survival
Time frame
3 yearsSecondary outcomes
1
3-year DFS
3-year disease-free survival
Time frame
3 years2
3-year LR
3-year local recurrence rate
Time frame
3 years3
3-year distant metastasis rate
3-year distant metastasis rate
Time frame
3 years4
neoadjuvant therapy rate
the percentage of patients who underwent standard neoadjuvant therapy
Time frame
at the time point of surgery of the primary lesionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov